Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Oct;55(10):4941.
doi: 10.1128/AAC.00512-11.

Clarification to the systematic review and meta-analysis involving tigecycline

Paul McGovern, Timothy Babinchak, Alvaro Quintana
Comment

Clarification to the systematic review and meta-analysis involving tigecycline

Paul McGovern et al. Antimicrob Agents Chemother. 2011 Oct.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

References

    1. Bergallo C., et al. 2009. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn. Microbiol. Infect. Dis. 63:52–61 - PubMed
    1. Breedt J., et al. 2005. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob. Agents Chemother. 49:4658–4666 - PMC - PubMed
    1. Cai Y., Wang R., Liang B., Bai N., Liu Y. 2011. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob. Agents Chemother. 55:1162–1172 - PMC - PubMed
    1. Chen Z., et al. 2010. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect. Dis. 10:217. - PMC - PubMed
    1. Florescu I., et al. 2008. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J. Antimicrob. Chemother. 62(Suppl. 1):i17–i28 - PubMed

MeSH terms